• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Canopy Completes Purchase of ebbu IP

Share:

December 3, 2018

Canopy Growth Corporation has closed the previously announced acquisition of the assets of ebbu, Inc., a leader in hemp research and innovation.

Intellectual Property and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. In addition, ebbu’s IP portfolio will contribute to the clinical formulations program executed by Canopy Health Innovations, a wholly owned subsidiary of the Company.

Canopy Growth operates a rapidly emerging, field-scale hemp operation based in Saskatchewan and by applying ebbu’s IP, the Company has the potential to vastly reduce the cost of CBD production, a sought-after cannabinoid in both the wellness and medical spaces.

Staying with Canopy Growth’s long-held position on business operations in the United States, this transaction would not have been finalized were it not in clear accordance with US federal law, along with the requisite exchange consent by the TSX. Canopy Growth, through a newly formed subsidiary, will employ ebbu’s assets and personnel to conduct R&D. There will be no production or sale of products resulting from such R&D in the United States unless and until it would be federally legal to do so.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The same technology platform will be utilized to produce other novel cannabinoids at scale and continue the process of unlocking the potential of lesser-understood elements in the cannabis plant, with the IP also being deployed at Canopy Growth’s Smiths Falls-based research and breeding facilities.

Canopy Growth has paid CDN $25 million in cash and issued 6,221,210 common shares for the assets being acquired. Up to a further CDN $100 million shall be payable under the purchase agreement if certain scientific related milestones are achieved within two years. Canopy Growth will have the option of satisfying such milestone payments in cash, shares or a combination of cash and shares. If such payments are satisfied in shares, the number of shares shall be calculated based on the volume weighted average price of the shares on the TSX for the 20 trading days immediately prior to the date of achievement of the applicable milestone.

Here’s to Future Growth (with snazzy new IP).

Date: December 3, 2018

Source: The Marijuana Index

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • PTC Therapeutics to Acquire Censa for $10 Million in Cash, $41 Million in Stock and MorePTC Therapeutics to Acquire Censa for $10 Million in Cash, $41 Million in Stock and More
  • Scipher Medicine Acquires Cross Bridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real TimeScipher Medicine Acquires Cross Bridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time
  • Health Benefits, Insurance Navigation Chatbot Sensely Lands $15MHealth Benefits, Insurance Navigation Chatbot Sensely Lands $15M
  • US Hospital EMR Market Share Growth Driven by Small HospitalsUS Hospital EMR Market Share Growth Driven by Small Hospitals
  • CAS Medical Surges As Edwards Lifesciences Agrees To Buy Medtech Company In $100M DealCAS Medical Surges As Edwards Lifesciences Agrees To Buy Medtech Company In $100M Deal
  • Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding SharesUrovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
  • Cohere Health Adds $10m to Streamline Care By Connecting Providers and PayersCohere Health Adds $10m to Streamline Care By Connecting Providers and Payers
  • JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as One Organization, Providing Seamless Experience for PartnersJSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as One Organization, Providing Seamless Experience for Partners

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications